Oxford researchers develop universal flu vax

Oxford University researchers have developed a universal flu vaccine using a potentially revolutionary approach. Traditional flu vaccines are designed to prompt an immune system response to proteins found on the outer shell of the virus. These proteins are prone to mutation, which means vaccines already on the market must be reformulated each year. This new vaccine, on the other hand, works by revealing the proteins inside the virus cell. This makes strains appear more consistent to the immune cell, which then learn to identify and destroy cells containing the virus proteins.

"With having to make new vaccine every year there's never enough to go around," study leader Dr. Sarah Gilbert told the BBC. "With this vaccine, we could end up having pretty much everyone vaccinated--a situation more like measles where you don't really see it anymore."

The team is set to begin testing the vaccine on a group of 12 people, but five to ten more years of research and trials lay ahead, according to Gilbert.

- check out the BBC article for more

Suggested Articles

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

AZ is among the companies leading the COVID-19 vaccine race, and after agreeing first to supply the U.K., it's now in talks for delivery worldwide.